Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.

The paired box containing gene PAX-5 encodes the transcription factor BSAP (B-cell-specific activator protein), which plays a key role in B-lymphocyte development. Despite its known involvement in a rare subtype of non-Hodgkin's lymphoma (NHL), a detailed examination of BSAP expression in NHL has not been previously reported. In this study, we analyzed normal and malignant lymphoid tissues and cell lines, including 102 cases of B-cell NHL, 23 cases of T- and null-cell NHL, and 18 cases of Hodgkin's disease. Normal lymphoid tissues showed strong nuclear BSAP expression in mantle zone B cells, less intense reactivity in follicular center B cells, and no expression in cells of the T-cell-rich zones. Monocytoid B cells showed weak expression, whereas plasma cells and extrafollicular large transformed B cells were negative. Of the 102 B-cell NHLs, 83 (81%) demonstrated BSAP expression. All of the 13 (100%) B-cell chronic lymphocytic leukemias (B-CLLs), 21 of (100%) mantle cells (MCLs), and 20 of 21 (95%) follicular lymphomas (FLs) were positive. Moderate staining intensities were found in most B-CLL and FL cases, whereas most MCLs showed strong reactions, paralleling the strong reactivity of nonmalignant mantle cells. Eight of 12 (67%) marginal zone lymphoma cases showed negative or low BSAP levels, and 17 of 24 (71%) large B-cell lymphomas displayed moderate to strong expression. None of the 23 T- and null-cell lymphomas reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic predominance and 5 of 14 (36%) classical cases showed weak nuclear or nucleolar BSAP reactions in a fraction of the tumor cells. Western blot analysis showed a 52-kD BSAP band in B-cell lines, but not in non-B-cell or plasma cell lines. We conclude that BSAP expression is largely restricted to lymphomas of B-cell lineage and that BSAP expression varies in B-cell subsets and subtypes of B-cell NHL. The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. This is a US government work. There are no restrictions on its use.

[1]  P Gruss,et al.  Pax: a murine multigene family of paired box-containing genes. , 1991, Genomics.

[2]  P. Gruss,et al.  Loss of p53 function through PAX‐mediated transcriptional repression. , 1995, The EMBO journal.

[3]  E. Wagner,et al.  Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5 BSAP , 1994, Cell.

[4]  S. Mundlos,et al.  PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. , 1992, Development.

[5]  M. Nobuyoshi,et al.  Altered expression of Pax-5 gene in human myeloma cells. , 1996, Blood.

[6]  M. Busslinger,et al.  the B-cell-specific transcription factor BSAP . The promoter of the CD 19 gene is a target for , 2022 .

[7]  J. Banchereau,et al.  Molecular Evidence That in Vivo Isotype Switching Occurs within the Germinal Centers , 1995, Annals of the New York Academy of Sciences.

[8]  Pavel Urbánek,et al.  Chromosomal localization of seven PAX genes and cloning of a novel family member, PAX-9 , 1993, Nature Genetics.

[9]  M. Busslinger,et al.  Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Strober,et al.  The murine Ig 3' alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP). , 1994, Journal of immunology.

[11]  P. Gruss,et al.  The oncogenic potential of Pax genes. , 1993, The EMBO journal.

[12]  P Gruss,et al.  Pax: gene regulators in the developing nervous system. , 1993, Journal of neurobiology.

[13]  K. Marcu,et al.  Properties of B cell stage specific and ubiquitous nuclear factors binding to immunoglobulin heavy chain gene switch regions. , 1992, International immunology.

[14]  E. Jaffe,et al.  Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. , 1997, Blood.

[15]  J. Stavnezer,et al.  A B-cell-specific nuclear protein that binds to DNA sites 5' to immunoglobulin S alpha tandem repeats is regulated during differentiation , 1989, Molecular and cellular biology.

[16]  J. Biegel,et al.  Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. , 1995, Human molecular genetics.

[17]  P. Isaacson,et al.  Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells , 1995, The Journal of experimental medicine.

[18]  N. Maizels,et al.  LR1, a lipopolysaccharide-responsive factor with binding sites in the immunoglobulin switch regions and heavy-chain enhancer. , 1991, Genes & development.

[19]  S. Schnitt,et al.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.

[20]  M. Goulding,et al.  The molecular basis of the undulated/Pax-1 mutation , 1991, Cell.

[21]  P. Isaacson,et al.  Sequence analysis of rearranged IgVH genes from microdissected human Peyer's patch marginal zone B cells. , 1996, Immunology.

[22]  C. Abbott,et al.  Linkage mapping of the Aldo-2, Pax-5, Ambp, and D4h9S3E loci on mouse chromosome 4 in the region of homology with human chromosome 9. , 1993, Genomics.

[23]  T. Strachan,et al.  PAX genes. , 1994, Current opinion in genetics & development.

[24]  M. Singh,et al.  NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3' alpha enhancer at early stages of B-cell differentiation , 1993, Molecular and cellular biology.

[25]  G. Dressler,et al.  Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Biegel,et al.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. , 1994, Cancer research.

[27]  M. Busslinger,et al.  C‐terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax‐5), Pax‐2 and Pax‐8. , 1996, The EMBO journal.

[28]  H. Stein,et al.  Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. , 1994, Blood.

[29]  J. Banchereau,et al.  B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. , 1996, Blood.

[30]  G. L. Wilson,et al.  Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. , 1994, Immunology today.

[31]  M. Busslinger,et al.  The role of BSAP (Pax-5) in B-cell development. , 1995, Current opinion in genetics & development.

[32]  A. Barberis,et al.  A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. , 1990, Genes & development.

[33]  F. Barr,et al.  Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Aguzzi,et al.  Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. , 1992, Genes & development.

[35]  J. Gnarra,et al.  Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. , 1995, Cancer research.

[36]  S. Hsu,et al.  The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. , 1994, Critical reviews in oncogenesis.

[37]  G. Chalepakis,et al.  Identification of DNA recognition sequences for the Pax3 paired domain. , 1995, Gene.

[38]  S. Bauer,et al.  Pre‐B lymphocyte‐specific transcriptional control of the mouse VpreB gene , 1992, European journal of immunology.

[39]  E. E. Max,et al.  The B cell-specific transcription factor BSAP regulates B cell proliferation , 1994, The Journal of experimental medicine.

[40]  P. Gruss,et al.  PAX5 expression correlates with increasing malignancy in human astrocytomas. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  E. E. Max,et al.  The role of BSAP in immunoglobulin isotype switching and B-cell proliferation. , 1995, Current topics in microbiology and immunology.

[42]  A. Kudo,et al.  A pre‐B‐ and B cell‐specific DNA‐binding protein, EBB‐1, which binds to the promoter of the VpreB1 gene , 1992, European journal of immunology.

[43]  A. Aguzzi,et al.  Deregulated expression of PAX5 in medulloblastoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Cattoretti,et al.  Correlation between presence of clonal rearrangements of immunoglobulin heavy chain genes and B-cell antigen expression in Hodgkin's disease. , 1995, American journal of clinical pathology.

[45]  R. Warnke,et al.  Primary large-cell lymphoma of the thymus: a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. , 1990, Human pathology.

[46]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[47]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[48]  P. Gaulard,et al.  Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas. , 1995, The American journal of pathology.

[49]  R. Dalla‐Favera,et al.  The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. , 1996, Blood.

[50]  K Offit,et al.  t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. , 1992, Blood.

[51]  E. E. Max,et al.  Pax5 (BSAP) regulates the murine immunoglobulin 3' alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  G. Dressler.  Pax-2 is a DNA-binding protein in embryonic kidney and Wilms tumor , 1992 .

[53]  J. Mallet,et al.  PAX-genes expression during human embryonic development, a preliminary report. , 1995, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[54]  P. Isaacson,et al.  Proliferation centres in B‐cell malignant lymphoma, lymphocytic (B‐CLL): an immunophenotypic study , 1994, Histopathology.